Taken together, these results suggest that AKT1 is a crucial regulator of STING signaling in endocrine‐resistant breast cancer cells and that knockdown of AKT1 or targeting AKT1 by MK2206 could release the activity of STING signaling. The gene discussed is AKT1; the disease is breast carcinoma.